Christina Fleres, MD
Obesity Medicine · North Kansas City, MONPI 1750910469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novo Nordisk at 37.0% of the total.
Across 78 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$564
- Lilly USA, LLC$543
- AbbVie$104
- AstraZeneca$73
- Madrigal Pharmaceuticals$53
- Phathom Pharmaceuticals, Inc.$49
- plus $137 from 5 others
What the payments were for
- Food & beverage$1,523100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $564 |
| Lilly USA, LLC | 24 | $543 |
| AbbVie | 5 | $104 |
| AstraZeneca | 5 | $73 |
| Madrigal Pharmaceuticals | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $49 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Corcept Therapeutics | 2 | $29 |
| Merck | 1 | $19 |
| Vertex | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$120
How this compares
Too few obesity medicine providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $204,635 |
| MounjaroTirzepatide | 96 | $111,912 |
| WegovySemaglutide | 11 | $15,994 |
| Metformin Hcl ErMetformin Hcl | 104 | $1,333 |
| Ondansetron OdtOndansetron | 14 | $137 |
| Topiramate | 29 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $564 | $220,630171 claims |
| Lilly USA, LLCMounjaro | $543 | $111,91296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Missourion file to place this against a meaningful peer group, so we don't.
Other obesity medicine in North Kansas City
- Brooke SweeneyKansas City$29K
- Russell ImbodenEureka$3K
- Rafael AlvarezSaint Joseph$3K
- Katy WilliamsMoberly$3K
- Lindsay OgleWildwood$1K
- Manasi HulyalkarFenton$831
- Brenda WellsSpringfield$60
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.